Zenapax Purple Book BLA 103749
- BLA number
- 103749
- Proprietary names
- Zenapax
- Proper names
- daclizumab
- Applicant
- Hoffmann-La Roche Inc.
- Center
- CDER
- First observed release
- 2020-05-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Zenapax | daclizumab | 351(a) | 25MG/5ML | Injection | Intravenous | Single-Dose Vial | Disc | Voluntarily Revoked | 1997-12-10 | |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2021-05-01 | U | 001 | Zenapax | 351(a) | Disc | Hoffmann-La Roche Inc. |
| 2020-09-01 | U | 001 | Zenapax | 351(a) | Disc | Hoffmann-La Roche, Inc. c/o Genentech, Inc. |
| 2020-05-01 | R | 001 | Zenapax | 351(a) | Disc | Hoffmann-La Roche, Inc. c/o Genentech, Inc. |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2020-08-01 | 001 | Zenapax | 351(a) | Disc | Voluntarily Revoked | 1997-12-10 |
| 2020-05-01 | 001 | Zenapax | 351(a) | Disc | Voluntarily Revoked | |